RxDoctor Payments DataLook up a doctor →

Jessica Oliver

Psychiatric/Mental Health · Thomasville, GANPI 1114585940

Payments from drug & device makers

$233,281in general payments, 2019–2025

Across 893 payments — averaging $261.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$95K
  • Axsome Therapeutics, Inc.$88K
  • Neurocrine Biosciences, Inc.$44K
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$1K
  • Teva Pharmaceuticals USA, Inc.$1K
  • Otsuka America Pharmaceutical, Inc.$860
  • plus $3K from 14 others

What the payments were for

  • Consulting fees$26,68811%
  • Speaking & faculty fees$170,45473%
  • Travel & lodging$20,2509%
  • Food & beverage$15,8417%
  • Education$490%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$233,281 in reported general payments places this provider in the 95th percentile of 900 psychiatric/mental health providers in Georgia.

See all psychiatric/mental health providers in Georgia

Medicare billing

Part B allowed, 2024
$5,941
Medicare patients
33
Services billed
92

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate35$310,321
VraylarCariprazine Hcl114$173,765
Invega SustennaPaliperidone Palmitate35$122,240
CaplytaLumateperone Tosylate43$76,920
AuvelityDextromethorphan Hbr/Bupropion11$13,184
Trazodone Hcl140$2,950
Aripiprazole57$2,667
Hydroxyzine Pamoate162$2,484
Oxcarbazepine64$2,455
Divalproex Sodium86$2,237
Ziprasidone Hcl50$2,210
Quetiapine Fumarate116$1,633
Prazosin Hcl47$1,561
Buspirone Hcl85$1,325
Venlafaxine Hcl ErVenlafaxine Hcl68$1,148

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Neurocrine Biosciences, Inc.Ingrezza$43,800$310,32135 claims
AbbVieVraylar$94,924$173,765114 claims
Johnson & JohnsonInvega Sustenna$758$122,24035 claims
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta$1,260$76,92043 claims
Axsome Therapeutics, Inc.Auvelity$88,054$13,18411 claims
Almatica Pharma LLCSertraline Hcl$39$69567 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 900 psychiatric/mental health providers in Georgia.

Other psychiatric/mental health in Thomasville

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →